PDGFR inhibitors are a class of targeted therapies designed to block the activity of the Platelet-Derived Growth Factor Receptors (PDGFR). These receptors are tyrosine kinase receptors that play crucial roles in cell growth, differentiation, and angiogenesis. Overactivation of PDGFR has been implicated in various types of cancer, making it a promising target for therapeutic intervention.
